Demographic, clinical and immunological parameters of enrolled patients with RA and PsA
| Remission RA cohort (n=25) | LDA RA cohort (n=10) | High/moderate RA cohort (n=50) | Remission PsA cohort (n=18) | p Value* | p Value** | p Value*** | p Value ^ | |
|---|---|---|---|---|---|---|---|---|
| Age, years (mean±SD) | 57.20±14.95 | 52.00±16.38 | 54.36±15.33 | 56.67±16.66 | 0.45 | 0.69 | 0.37 | 0.80 |
| Gender, female (%) | 21 (84.0) | 6 (60.0) | 40 (80.00) | 11 (61.1) | 0.68 | 0.17 | 0.13 | 0.08 |
| Disease duration, years (mean±SD) | 9.70±2.81 | 9.52±3.03 | 2.19±2.82 | 8.50±3.01 | <0.001 | <0.001 | 0.06 | 0.89 |
| Treatment duration, years (mean±SD) | 7.01±3.41 | 6.98±2.75 | – | 6.83±2.95 | – | – | 0.98 | 0.63 |
| AB positivity, n (%) | 17 (68.0) | 5 (50.0) | 28 (56.0) | 0 (0.0) | 0.31 | 0.72 | 0.27 | <0.001 |
| DAS (mean±SD) | 1.09±0.40 | 1.90±0.31 | 3.52±1.10 | 1.10±0.53 | <0.001 | <0.001 | <0.001 | 0.87 |
| DAS28 (mean±SD) | 2.17±0.82 | 3.18±0.48 | 5.00±1.24 | 2.16±0.86 | <0.001 | <0.001 | <0.001 | 0.51 |
| GH (mean±SD) | 32.00±12.73 | 37.88±27.90 | 55.80±23.56 | 33.44±31.93 | 0.001 | 0.02 | 0.37 | 0.89 |
| TJC28 (mean±SD) | 0.04±0.20 | 1.20±1.23 | 7.14±6.21 | 0.39±0.61 | <0.001 | <0.001 | 0.01 | 0.10 |
| TJC44 (mean±SD) | 0.16±0.47 | 1.60±1.95 | 8.66±8.84 | 0.39±0.61 | <0.001 | <0.001 | 0.02 | 0.11 |
| SJC28 (mean±SD) | 0.12±0.33 | 1.00±1.05 | 7.04±6.03 | 0.22±0.43 | <0.001 | <0.001 | 0.02 | 0.38 |
| SJC44 (mean±SD) | 0.16±0.37 | 1.00±1.05 | 8.68±8.72 | 0.22±0.43 | <0.001 | <0.001 | 0.02 | 0.61 |
| ESR, mm/first hour (mean±SD) | 17.00±16.10 | 16.20±16.28 | 54.65±31.05 | 14.17±13.62 | <0.001 | <0.001 | 0.90 | 0.62 |
| CRP, mg/L (mean±SD) | 2.14±2.00 | 2.58±2.13 | 21.43±21.54 | 2.77±3.20 | <0.001 | 0.002 | 0.53 | 0.96 |
| BMI (mean±SD) | 25.78±4.11 | 29.54±8.19 | 26.55±5.65 | 26.64±4.25 | 0.65 | 0.19 | 0.15 | 0.42 |
| Treatment regimen | ||||||||
| MTX dose, mg/week | 14.42±3.56 | 14.38±4.96 | – | 14.79±3.45 | – | – | 0.97 | 0.97 |
| Etanercept 50 mg/week | 13 (52.0) | 6 (60.0) | – | 10 (55.6) | – | – | 0.67 | 0.82 |
| Adalimumab 40 mg/2 weeks | 12 (48.0) | 4 (40.0) | – | 8 (44.4) | – | – | 0.67 | 0.82 |
p*: Patients with RA in remission versus patients with RA with high/moderate disease; p**: Patients with RA in LDA versus patients with RA with high/moderate disease; p***: Patients with RA in remission versus patients with RA in LDA; p^: Patients with RA in remission versus patients with PsA in remission; Bold: p<0.05.
AB, autoantibody; BMI, body mass index; CRP, C reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; GH, global health; LDA, low disease activity; MTX, methotrexate; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint count.